There is no single “best” medication for JRA/JIA. The best approach is an individualized, treat-to-target management plan aligned with subtype and disease activity. The strategic goals are to control inflammation, prevent joint damage, protect growth, and sustain daily function with minimal disruption. This plan typically integrates medication strategy, physical therapy and exercise, school and social adaptations, and structured monitoring protocols. Some children require disease-modifying therapy (DMARD-based approach), and biologic options may be considered in more severe or refractory disease. Eye surveillance is also a critical operational component for subtypes with uveitis risk. The most effective model is a pediatric rheumatology-led system built on measurable targets and regular adjustment based on response and safety monitoring.